Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

FASL Antikörper (AA 132-146)

FASL Reaktivität: Maus FACS Wirt: Hamster Monoclonal FLIM4 unconjugated
Produktnummer ABIN1105951
  • Target Alle FASL Antikörper anzeigen
    FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))
    Bindungsspezifität
    • 16
    • 9
    • 7
    • 6
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 132-146
    Reaktivität
    • 103
    • 51
    • 35
    • 18
    • 6
    • 4
    • 3
    • 2
    • 1
    Maus
    Wirt
    • 68
    • 36
    • 9
    • 5
    • 4
    • 3
    • 1
    Hamster
    Klonalität
    • 75
    • 51
    Monoklonal
    Konjugat
    • 72
    • 14
    • 10
    • 8
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser FASL Antikörper ist unkonjugiert
    Applikation
    • 83
    • 63
    • 28
    • 25
    • 22
    • 17
    • 13
    • 13
    • 10
    • 7
    • 7
    • 6
    • 5
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Flow Cytometry (FACS)
    Sequenz
    PSTPSEKKEP RSVAH
    Spezifität
    This antibody reacts with mouse FasL of B6, C3H and MRL mice as well as Balb/c and DBA/1 mice. It also detects gld-type mouse FasL mutant by flow cytometric analysis. We have tested the reactivity on flow cytometry using mouse cell line W40LFL, which is overexpressor of mouse FasL extracellular region (See ref. 1) for more information about this cell line).
    Kreuzreaktivität (Details)
    Species reactivity (tested):Mouse
    Aufreinigung
    Protein A agarose
    Immunogen
    Synthetic peptide corresponding to the amino acids 132-146 of mouse Fas ligand
    Klon
    FLIM4
    Isotyp
    IgG
    Top Product
    Discover our top product FASL Primärantikörper
  • Applikationshinweise
    Optimal working dilution should be determined by the investigator.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Konzentration
    1.0 mg/mL
    Buffer
    PBS containing 50 % glycerol, pH 7.2. No preservative is contained.
    Konservierungsmittel
    Without preservative
    Handhabung
    Avoid repeated freezing and thawing.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    Store (in aliquots) at -20 °C.
  • Target
    FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))
    Andere Bezeichnung
    CD178 / Fas Ligand (FASL Produkte)
    Synonyme
    ALPS1B antikoerper, APT1LG1 antikoerper, APTL antikoerper, CD178 antikoerper, CD95-L antikoerper, CD95L antikoerper, FASL antikoerper, TNFSF6 antikoerper, fasl antikoerper, Fas-L antikoerper, Faslg antikoerper, Tnfsf6 antikoerper, gld antikoerper, Apt1Lg1 antikoerper, Fasl antikoerper, FASLG antikoerper, zgc:162027 antikoerper, Fas ligand antikoerper, Fas ligand L homeolog antikoerper, Fas ligand (TNF superfamily, member 6) antikoerper, FASLG antikoerper, faslg.L antikoerper, Fasl antikoerper, Faslg antikoerper, faslg antikoerper
    Hintergrund
    Fas ligand (FasL/CD178/CD95L) is a type II-membrane protein, whose N terminus is in the cytoplasm and its C-terminal region extends into the extracellular space. Its receptor Fas, also termed Apo-1 or CD95, is a cell-surface type I-membrane protein and a member of the tumor necrosis factor (TNF) and nerve growth factor (NGF) receptor family. It is known that engagement of Fas by FasL results in apoptotic cell death. Binding of a trimeric FasL to Fas induces trimerization of Fas, and FADD/MORT1 binds to the trimerized Fas cytoplasmic region through the interaction of the respective death domains. Caspase-8 is then recruited to FADD/MORT1 through binding of each death effector domains (DED), which in turn may induce self-activation of the protease domain and eventually leads cell to apoptosis. FasL is predominantly expressed in activated T lymphocytes and Natural Killer (NK) cells, although it is expressed in the tissues of the immune-privilege sites such as the testis and eye. Furthermore, a variety of cancers such as melanomas were found to express FasL in addition to Fas. On the other hand, Fas is expressed in various tissues with abundant expression in the thymus, liver, heart, and kidney. It is reported that Fas/FasL system is involved in the deletion of activated or autoreactive T and B cells. Mature T cells of normal mice are known to die, after they accomplish their tasks. On the contrary, mature T cells from lpr and gld mice, which are deficient of Fas and FasL respectively, do not die after activation, and activated cells accumulate in the lymph nodes and spleens of these mice. Moreover T cell hybridomas activated in the presence of Fas-neutralizing molecule, do not die. In addition to T cells, the Fas-deficient mice accumulate B cells and have elevated levels of immunoglobulins (Ig) of various classes that include anti-ssDNA and anti-dsDNA antibodies. FasL can be used as an immune-suppressive agent. Rejection of transplants is mediated by activated T cells that may express functional Fas. If a transplanted tissue is engineered to express FasL or is co-transplanted with FasL expressing cells, the transplant may be tolerated. Also Fas/ FasL system has been shown to play a role in human diseases such as fulminant hepatitis, AIDS, cancers and other diseases involving CTL-induced tissue destruction.Synonyms: APT1LG1, APTL, Apoptosis antigen ligand, CD95L protein, FASL, FASLG, Fas antigen ligand, TNFSF6, Tumor necrosis factor ligand superfamily member 6
    Gen-ID
    356
    NCBI Accession
    NP_000630
    UniProt
    P48023
    Pathways
    Apoptose, EGFR Signaling Pathway, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity
Sie sind hier:
Kundenservice